Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Livzon Out-licenses PD-1 to Bright Peak for PD-1 Targeted Immunocytokines

publication date: Nov 19, 2021

Livzon Mabpharm of Zhuhai, Guangdong Provence, out-licensed its clinical stage PD-1 to Bright Peak Therapeutics of San Diego to develop PD-1 targeted immunocytokines. The PD-1 ICs will contain optimized cytokine payloads developed by Bright Peak and conjugated to the PD-1 to treat a variety of cancers. Bright Peak will own global rights to the PD-1 ICs, while Livzon will have first negotiation rights in China. Bright Peak will be responsible for all development activities. Livzon will receive an upfront payment plus milestones and royalties. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital